WO2017070003A1 - Utilisation de promédicaments composés d'acide 1,3-propane disulfonique ou de sels pharmaceutiquement acceptable de celui-ci pour le traitement de la sarcoïdose - Google Patents

Utilisation de promédicaments composés d'acide 1,3-propane disulfonique ou de sels pharmaceutiquement acceptable de celui-ci pour le traitement de la sarcoïdose Download PDF

Info

Publication number
WO2017070003A1
WO2017070003A1 PCT/US2016/056899 US2016056899W WO2017070003A1 WO 2017070003 A1 WO2017070003 A1 WO 2017070003A1 US 2016056899 W US2016056899 W US 2016056899W WO 2017070003 A1 WO2017070003 A1 WO 2017070003A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically acceptable
prodrug
acceptable salt
propanedisulfonic acid
group
Prior art date
Application number
PCT/US2016/056899
Other languages
English (en)
Inventor
Reinaldo DIAZ
Original Assignee
Kiacta Sárl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kiacta Sárl filed Critical Kiacta Sárl
Publication of WO2017070003A1 publication Critical patent/WO2017070003A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des méthodes de traitement de la sarcoïdose. Dans certains aspects et modes de réalisation, l'invention concerne des compositions contenant un promédicament composé d'acide 1,3-propane disulfonique ou d'un sel pharmaceutiquement acceptable de celui-ci, et/ou l'utilisation desdites compositions pour le traitement de la sarcoïdose. Selon un autre aspect, l'invention concerne des compositions contenant un promédicament composé d'acide 1,3-propane disulfonique ou d'un sel pharmaceutiquement acceptable de celui-ci ainsi qu'un second principe actif. Dans encore un autre aspect, l'invention concerne des kits contenant des agents utilisables pour le traitement de la sarcoïdose.
PCT/US2016/056899 2015-10-20 2016-10-13 Utilisation de promédicaments composés d'acide 1,3-propane disulfonique ou de sels pharmaceutiquement acceptable de celui-ci pour le traitement de la sarcoïdose WO2017070003A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562243882P 2015-10-20 2015-10-20
US62/243,882 2015-10-20

Publications (1)

Publication Number Publication Date
WO2017070003A1 true WO2017070003A1 (fr) 2017-04-27

Family

ID=58557658

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/056899 WO2017070003A1 (fr) 2015-10-20 2016-10-13 Utilisation de promédicaments composés d'acide 1,3-propane disulfonique ou de sels pharmaceutiquement acceptable de celui-ci pour le traitement de la sarcoïdose

Country Status (1)

Country Link
WO (1) WO2017070003A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3137071A4 (fr) * 2014-04-30 2017-11-01 Icahn School of Medicine at Mount Sinai Utilisation d'acide 1,3-propane disulfonique ou de sels pharmaceutiquement acceptable de celui-ci pour le traitement de la sarcoïdose
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
US11926616B2 (en) 2018-03-08 2024-03-12 Incyte Corporation Aminopyrazine diol compounds as PI3K-γ inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140004182A1 (en) * 2009-11-19 2014-01-02 Jerome B. Zeldis Methods for the treatment of sarcoidosis
US20140329746A1 (en) * 2004-12-22 2014-11-06 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US20150031702A1 (en) * 2012-02-06 2015-01-29 Glaxosmithkline Intellectual Property (No.2) Limited Pi3k inhibitors for treating cough
WO2015168315A1 (fr) * 2014-04-30 2015-11-05 Icahn School Of Medicine At Mount Sinai Utilisation d'acide 1,3-propane disulfonique ou de sels pharmaceutiquement acceptable de celui-ci pour le traitement de la sarcoïdose

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140329746A1 (en) * 2004-12-22 2014-11-06 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US20140004182A1 (en) * 2009-11-19 2014-01-02 Jerome B. Zeldis Methods for the treatment of sarcoidosis
US20150031702A1 (en) * 2012-02-06 2015-01-29 Glaxosmithkline Intellectual Property (No.2) Limited Pi3k inhibitors for treating cough
WO2015168315A1 (fr) * 2014-04-30 2015-11-05 Icahn School Of Medicine At Mount Sinai Utilisation d'acide 1,3-propane disulfonique ou de sels pharmaceutiquement acceptable de celui-ci pour le traitement de la sarcoïdose

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3137071A4 (fr) * 2014-04-30 2017-11-01 Icahn School of Medicine at Mount Sinai Utilisation d'acide 1,3-propane disulfonique ou de sels pharmaceutiquement acceptable de celui-ci pour le traitement de la sarcoïdose
US10682321B2 (en) 2014-04-30 2020-06-16 Icahn School Of Medicine At Mount Sinai Use of 1,3-propanedisulfonic acid or pharmaceutically acceptable salts thereof for the treatment of sarcoidosis
US11413260B2 (en) 2014-04-30 2022-08-16 Icahn School Of Medicine At Mount Sinai Use of 1,3-propanedisulfonic acid or pharmaceutically acceptable salts thereof for the treatment of sarcoidosis
US11926616B2 (en) 2018-03-08 2024-03-12 Incyte Corporation Aminopyrazine diol compounds as PI3K-γ inhibitors
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors

Similar Documents

Publication Publication Date Title
EP1836161B1 (fr) Methodes et compositions de traitement de maladies liees a l'amyloide
KR101124935B1 (ko) 아밀로이드 관련 질환의 치료 방법 및 조성물
WO2017070003A1 (fr) Utilisation de promédicaments composés d'acide 1,3-propane disulfonique ou de sels pharmaceutiquement acceptable de celui-ci pour le traitement de la sarcoïdose
CZ177596A3 (en) 2,4-disulfonylphenylbutylnitrone, salts thereof and the use of the salts as medicaments
US20050038117A1 (en) Methods and compositions for treating amyloid-related diseases
EA025636B1 (ru) Фармацевтические композиции, содержащие лиганды рецептора дофамина
US7414076B2 (en) Methods and compositions for treating amyloid-related diseases
JP5399564B2 (ja) トラマドールとコキシブとの共結晶
US20050038000A1 (en) Methods and compositions for the treatment of amyloid-and epileptogenesis-associated diseases
US20240067635A1 (en) Cromolyn derivatives and uses thereof
US11413260B2 (en) Use of 1,3-propanedisulfonic acid or pharmaceutically acceptable salts thereof for the treatment of sarcoidosis
AU2004251717B2 (en) Treatment of amyloid- and epileptogenesis-associated diseases
AU2011250847B2 (en) Methods and compositions for treating amyloid-related diseases
CN104011043B (zh) 作为抗毒蕈碱剂的1-氮杂杂环基乙酸的奎宁环酯、它们的制备方法及其药用组合物
IE44093B1 (en) New salts of the dimethylaminoethyl ester of p-chlorophenoxy acetic acid

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16858014

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 23/07/2018)

122 Ep: pct application non-entry in european phase

Ref document number: 16858014

Country of ref document: EP

Kind code of ref document: A1